Nicotinamide riboside (NR) is an NAD+ precursor vitamin, and the ingredient most often mentioned alongside NMN when brands abroad ask for a “healthy ageing” product made in Japan. Both raise the coenzyme NAD+, which every cell needs and which declines with age, but they are different molecules with separate regulatory histories.
This guide is for brand owners planning an NR product made in Japan. It covers what the human trials show, how NR compares with NMN, Japan’s regulatory framing, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a nicotinamide riboside product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Human trials consistently show that oral NR raises blood NAD+ levels, but functional results beyond that are limited, and one trial in older adults found no cognitive benefit.
| Study | Design | Reported result |
|---|---|---|
| Pharmacokinetic trial, Nature Communications 2016 (PMID 27721479) | Single oral doses of 100, 300 or 1,000 mg NR in humans, plus a one-person pilot dose | Dose-dependent increases in the blood NAD+ metabolome at all three doses; blood NAD+ rose as much as 2.7-fold with a single dose in the pilot case |
| Randomised, double-blind, placebo-controlled trial (“NICE” trial), Nature Communications 2024 (PMID 38871717) | 90 adults with peripheral artery disease; NR with or without resveratrol, or placebo, for 6 months | NR alone significantly improved 6-minute walk distance versus placebo (+17.6 metres); resveratrol added no further benefit; the effect was larger in participants with high pill adherence |
| Randomised, placebo-controlled pilot trial, GeroScience 2024 (PMID 37994989) | 20 older adults with mild cognitive impairment; NR escalated to 1 g/day for 10 weeks | Blood NAD+ rose 2.6-fold with NR; cognitive test scores (including MoCA) stayed stable in both groups; walking speed improved in the placebo group but not in the NR group; a reduction in blood flow to one brain region did not survive correction for multiple comparisons |
Three points to keep in view:
- What actually improved. Raising NAD+ is the most consistent finding across all three trials. Walking distance improved only in a disease population (peripheral artery disease) after 6 months; cognition did not improve in older adults with mild cognitive impairment over 10 weeks.
- Size and duration. The cognition trial studied only 20 people for 10 weeks. The walking-distance trial studied 90 people for 6 months. Neither is large by pharmaceutical standards.
- Funding. All three trials disclosed a financial relationship between at least one author and the manufacturer of the nicotinamide riboside material used, including stock, employment or consulting ties in the earliest pharmacokinetic study. Read the funding line of any study you plan to cite.
Checked against the published abstracts on 25 September 2026.
NR compared with NMN
NR and NMN are different molecules that both raise NAD+, and neither has been shown in trials to outperform the other for functional outcomes.
Both are NAD+ precursors and both have been studied in small human trials that show reliable increases in blood NAD+ with limited functional results beyond that. They differ in molecular structure, absorption pathway and regulatory history in some markets. Brands choosing between the two should base the decision on their target market’s regulatory status for each ingredient and the specific studies they intend to cite, not on an assumption that one is proven superior. See our separate NMN guide for that ingredient’s own trial evidence and market-status history.
What Japanese products say
Nicotinamide riboside chloride has been treated as a food ingredient in Japan since March 2020, alongside NMN, but Foods with Function Claims notifications specific to NR are limited.
Japan’s Ministry of Health, Labour and Welfare revised its food-drug classification (食薬区分) on 31 March 2020, adding nicotinamide riboside chloride, together with NMN and teff, to the list of substances not treated as pharmaceuticals, provided no medicinal effect is claimed. That classification is what allows NR to be used in foods in Japan.
Two lessons for a brand abroad:
- Being on the non-pharmaceutical list is not the same as a notified function. It permits NR as a food ingredient; it does not itself grant any specific wording about NAD+, ageing, walking or cognition.
- A Japanese food-ingredient status is not a global endorsement. Your market’s rules for NR govern your label abroad.
💬 Need an evidence summary for your regulatory adviser that separates Japan’s food-ingredient status from the underlying trials? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe NR by what trials actually measured — mainly blood NAD+ levels — not by ageing, lifespan or disease outcomes no trial has confirmed.
| Safer wording | Wording to avoid |
|---|---|
| ”Contains nicotinamide riboside, studied for its effect on blood NAD+ levels" | "Reverses ageing”, “extends lifespan”, “anti-ageing" |
| "NR amount per serving, with the study it is based on” | Disease names, or “treats”, “prevents” or “improves memory” without naming the limits |
| ”Early research; functional results are still limited" | "Clinically proven” without naming the study, its size and its limits |
How nicotinamide riboside is formulated
NR is dosed from tens to hundreds of milligrams and is sensitive to moisture and heat, so stability is as much a part of the specification as the dose.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule or tablet | Straightforward, familiar format for the typical daily dose | Needs a moisture-resistant blister or bottle with desiccant |
| Powder in a capsule or sachet | Flexible dosing for higher amounts | Taste and stability once opened |
Decisions that shape the specification:
- Source and salt form. NR for foods is typically supplied as a stabilised chloride salt, produced by fermentation or chemical synthesis. Ask the supplier for its production method, purity and a certificate of analysis.
- Amount per serving. Doses in the trials above ranged from single 100–1,000 mg doses to 1 g/day sustained. Match the amount to a specific study, and disclose that higher long-term amounts are less studied for safety.
- Stability and packaging. NR salts are sensitive to moisture and heat. Blister packs, foil sachets or bottles with desiccant, and storage guidance on the label, all affect shelf life.
- Your target market’s status for NR. Confirm current status with your regulatory adviser before you commit to a market, since NAD+-precursor ingredients have seen shifting rules in more than one country.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Nicotinamide riboside chloride has been treated as a food ingredient in Japan since March 2020. Companion ingredients in an ageing-focused formula — botanical extracts especially — need their own check, since some botanicals sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and compare with our NMN and CoQ10 guides if you are building a combined healthy-ageing formula.
Before you ask for a quotation
A factory can quote accurately once the source, the amount, the form and the packaging are fixed.
- NR source, salt form and certificate of analysis
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Packaging and stability requirements (moisture, heat)
- Countries you will sell in, and NR’s current status in each
💬 Ready to design a Japan-made nicotinamide riboside product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does nicotinamide riboside raise NAD+ levels in humans?
Yes. Every trial reviewed here found it does, from a single-dose pharmacokinetic study to a 10-week trial in older adults. That is the most consistently reported finding for this ingredient.
2. Does NR improve cognition or memory?
A 2024 trial in 20 older adults with mild cognitive impairment found no improvement in cognitive test scores after 10 weeks, despite a 2.6-fold rise in blood NAD+. Describe NR by its effect on NAD+ levels, not by cognitive outcomes.
3. Is NR better than NMN?
Neither has been shown in trials to outperform the other for functional outcomes. Both raise NAD+ reliably with limited functional evidence beyond that; the choice usually comes down to your target market’s regulatory status for each.
4. Is nicotinamide riboside permitted in foods in Japan?
Yes. Japan’s Ministry of Health, Labour and Welfare added nicotinamide riboside chloride to its non-pharmaceutical substance list on 31 March 2020, in the same revision that added NMN.
5. What amount of NR do human trials use?
Single doses of 100 mg to 1,000 mg in the earliest pharmacokinetic study, and up to 1 g/day sustained over weeks in later trials. Match your specification to a specific study rather than the highest dose you find.
Sources: “Nicotinamide riboside is uniquely and orally bioavailable in mice and humans”, Nature Communications 2016, 7:12948 (PMID 27721479); “Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial”, Nature Communications 2024, 15:5046 (PMID 38871717); “A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment”, GeroScience 2024, 46(1):665-682 (PMID 37994989); Ministry of Health, Labour and Welfare, food-drug classification notification of 31 March 2020 (mhlw.go.jp). Checked on 25 September 2026.